19 July 2024
19 July 2024
The company’s medical devices segment reported a significant increase of 10.2% on a reported basis.
The device is said to be the first transcatheter pulmonary artery banding system intended to treat HFrEF.
The new platform provides clinicians with a non-invasive solution to quantify and characterise plaque in the coronary arteries.
The multi-centre trial will compare 50,000 medicare beneficiaries examined with Grail’s diagnostic Galleri test designed to catch cancer earlier.
ExThera’s Seraph 100 media resulted in a 94% average reduction in CRCs from pancreatic cancer patients in vivo blood samples.
As the VR market begins to plateau among consumers, companies such as Lenovo are looking to advance their technology as a therapeutic device in assisted-living facilities.
The clinical trial aims to assess the safety and efficacy of the Signati Separo system for vasectomy.
Lisata will use Haystack’s minimal residual disease (MRD) test to evaluate the efficacy of certepetide at multiple points during a Phase II trial.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
